Cue Biopharma (CUE) Competitors $0.77 -0.03 (-3.77%) Closing price 07/11/2025 04:00 PM EasternExtended Trading$0.76 -0.01 (-0.78%) As of 07/11/2025 04:22 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock CUE vs. MDWD, KOD, ACIU, CRGX, LRMR, CTMX, DRUG, SOPH, FDMT, and YMABShould you be buying Cue Biopharma stock or one of its competitors? The main competitors of Cue Biopharma include MediWound (MDWD), Kodiak Sciences (KOD), AC Immune (ACIU), CARGO Therapeutics (CRGX), Larimar Therapeutics (LRMR), CytomX Therapeutics (CTMX), Bright Minds Biosciences (DRUG), SOPHiA GENETICS (SOPH), 4D Molecular Therapeutics (FDMT), and Y-mAbs Therapeutics (YMAB). These companies are all part of the "pharmaceutical products" industry. Cue Biopharma vs. Its Competitors MediWound Kodiak Sciences AC Immune CARGO Therapeutics Larimar Therapeutics CytomX Therapeutics Bright Minds Biosciences SOPHiA GENETICS 4D Molecular Therapeutics Y-mAbs Therapeutics MediWound (NASDAQ:MDWD) and Cue Biopharma (NASDAQ:CUE) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, valuation, earnings, risk, dividends, analyst recommendations, profitability and media sentiment. Does the media prefer MDWD or CUE? In the previous week, MediWound and MediWound both had 2 articles in the media. MediWound's average media sentiment score of 1.35 beat Cue Biopharma's score of 0.94 indicating that MediWound is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment MediWound 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Cue Biopharma 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do analysts rate MDWD or CUE? MediWound presently has a consensus target price of $31.80, suggesting a potential upside of 58.76%. Cue Biopharma has a consensus target price of $3.00, suggesting a potential upside of 291.64%. Given Cue Biopharma's higher possible upside, analysts plainly believe Cue Biopharma is more favorable than MediWound.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score MediWound 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 3.00Cue Biopharma 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00 Is MDWD or CUE more profitable? MediWound has a net margin of -110.45% compared to Cue Biopharma's net margin of -507.87%. MediWound's return on equity of -74.12% beat Cue Biopharma's return on equity.Company Net Margins Return on Equity Return on Assets MediWound-110.45% -74.12% -30.92% Cue Biopharma -507.87%-228.43%-114.66% Do institutionals and insiders hold more shares of MDWD or CUE? 46.8% of MediWound shares are owned by institutional investors. Comparatively, 35.0% of Cue Biopharma shares are owned by institutional investors. 9.2% of MediWound shares are owned by insiders. Comparatively, 10.8% of Cue Biopharma shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term. Which has more risk and volatility, MDWD or CUE? MediWound has a beta of 0.32, suggesting that its share price is 68% less volatile than the S&P 500. Comparatively, Cue Biopharma has a beta of 1.43, suggesting that its share price is 43% more volatile than the S&P 500. Which has higher valuation & earnings, MDWD or CUE? MediWound has higher revenue and earnings than Cue Biopharma. MediWound is trading at a lower price-to-earnings ratio than Cue Biopharma, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioMediWound$20.22M10.71-$30.22M-$2.09-9.58Cue Biopharma$9.29M6.21-$40.67M-$0.67-1.14 SummaryMediWound beats Cue Biopharma on 9 of the 14 factors compared between the two stocks. Get Cue Biopharma News Delivered to You Automatically Sign up to receive the latest news and ratings for CUE and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding CUE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CUE vs. The Competition Export to ExcelMetricCue BiopharmaMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$59.98M$2.97B$5.62B$9.10BDividend YieldN/A2.39%5.24%4.00%P/E Ratio-1.1420.7128.1320.27Price / Sales6.21288.39428.6398.72Price / CashN/A42.8637.4658.16Price / Book2.747.638.045.49Net Income-$40.67M-$55.05M$3.18B$250.45M7 Day Performance11.34%8.43%3.62%4.78%1 Month Performance20.50%5.42%4.05%7.67%1 Year Performance-18.53%2.03%30.00%16.43% Cue Biopharma Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CUECue Biopharma4.0791 of 5 stars$0.77-3.8%$3.00+291.6%-19.2%$59.98M$9.29M-1.1460Gap DownMDWDMediWound1.8474 of 5 stars$19.27-0.4%$31.80+65.0%-0.3%$209.02M$20.22M-9.2280KODKodiak Sciences4.0934 of 5 stars$3.71-6.1%$9.00+142.6%+64.1%$208.42MN/A-1.0290News CoverageACIUAC Immune2.251 of 5 stars$1.99-3.9%$12.00+503.0%-42.5%$207.85M$31.02M-3.43140Analyst RevisionCRGXCARGO Therapeutics2.2334 of 5 stars$4.39-1.6%$15.00+241.7%-73.3%$205.65MN/A-0.95116News CoveragePositive NewsAnalyst ForecastLRMRLarimar Therapeutics1.9738 of 5 stars$3.20flat$18.50+478.1%-65.5%$204.89MN/A-2.1530CTMXCytomX Therapeutics4.2725 of 5 stars$2.37-5.2%$5.33+125.0%+72.9%$201.55M$138.10M4.94170News CoveragePositive NewsDRUGBright Minds Biosciences2.2846 of 5 stars$27.33-3.7%$83.25+204.6%+2,386.0%$199.84MN/A-75.91N/ASOPHSOPHiA GENETICS2.7457 of 5 stars$3.25+8.7%$7.00+115.4%-25.9%$199.39M$65.17M-3.25520High Trading VolumeFDMT4D Molecular Therapeutics2.1813 of 5 stars$3.95-6.8%$29.56+648.2%-83.4%$196.42M$40K-1.24120YMABY-mAbs Therapeutics4.0248 of 5 stars$4.22-1.9%$15.60+269.7%-63.9%$194.72M$87.68M-6.59150 Related Companies and Tools Related Companies MediWound Alternatives Kodiak Sciences Alternatives AC Immune Alternatives CARGO Therapeutics Alternatives Larimar Therapeutics Alternatives CytomX Therapeutics Alternatives Bright Minds Biosciences Alternatives SOPHiA GENETICS Alternatives 4D Molecular Therapeutics Alternatives Y-mAbs Therapeutics Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CUE) was last updated on 7/12/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredI was wrong about TrumpI made a mistake. A mistake I feel very foolish about. After speaking with Donald Trump and some of his ...Porter & Company | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | Sponsored$100 Trillion “AI Metal” Found in American Ghost TownJeff Brown recently traveled to a ghost town in the middle of an American desert… To investigate what could...Brownstone Research | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredBank of America Says Gold Could Hit $4,000. Here How to Get PaidBank of America believes gold could hit $4,000 an ounce in the next 12 months. That's an 18% jump from toda...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cue Biopharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cue Biopharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
